Immunovant, Inc. Stock News

NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today anno

Wells Fargo & Company assumed coverage on shares of Immunovant (NASDAQ:IMVT) in a report published on Wednesday morning, Price Targets.com reports. The firm issued an equal weight rating and a $9.00 target price on the stock. Other analysts also recently issued research reports about the company. Chardan Capital dropped their target price on Immunovant from []

Marshall Wace LLP lessened its position in Immunovant, Inc. (NASDAQ:IMVT) by 19.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,167 shares of the companys stock after selling 4,027 shares during the quarter. Marshall Wace LLPs holdings in Immunovant were worth $181,000 as []

Morgan Stanley raised its stake in Immunovant, Inc. (NASDAQ:IMVT) by 104.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,542,372 shares of the companys stock after purchasing an additional 789,721 shares during the quarter. Morgan Stanleys holdings in Immunovant were worth []

State Street Corp increased its position in Immunovant, Inc. (NASDAQ:IMVT) by 21.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,390,637 shares of the companys stock after acquiring an additional 774,877 shares during the period. State Street Corps holdings in Immunovant []

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today ann

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?

Precarious Market Action

Immunovant's (IMVT) earnings miss estimates in first-quarter fiscal 2022 (ended Jun 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.

Immunovant, Inc. (IMVT) CEO Pete Salzmann on Q1 2022 Results - Earnings Call Transcript

Company Ended the Quarter With Cash of Approximately $379 Million and Subsequently Received a Direct Investment of $200 Million from Roivant Company Ended the Quarter With Cash of Approximately $379 M

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today anno

An analyst note is extending yesterday's sell-off.

Drugmaker Roviant Sciences had been plotting a novel take on the popular SPAC deal, according to a report from Bloomberg.

Shareholders are throwing in the towel after not getting the deal they were expecting.